PAX4 has the potential to function as a tumor suppressor in human melanoma

International Journal of Oncology

Volumn 33, Issue 5, 2008, Pages 1065-1071

  Hata, Shinya ^a,b   Hamada, Jun Ichi ^a   Maeda, Kazuhiko ^a,b   Murai, Taichi ^a   Tada, Mitsuhiro ^a   Furukawa, Hiroshi ^b   Tsutsumida, Arata ^b   Saito, Akira ^b   Yamamoto, Yuhei ^b   Moriuchi, Tetsuya ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Melanoma; PAX4; Tumor suppressor

Indexed keywords

AZACITIDINE; TRANSCRIPTION FACTOR PAX4; TRANSCRIPTION FACTOR PAX9; ENZYME INHIBITOR; HOMEODOMAIN PROTEIN; MESSENGER RNA; PAIRED BOX TRANSCRIPTION FACTOR; PAX4 PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL GROWTH; CLINICAL ARTICLE; CONTROLLED STUDY; DNA METHYLATION; DNA SYNTHESIS; FEMALE; FLOW CYTOMETRY; GENE FUNCTION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MALE; MELANOMA; NUCLEOTIDE SEQUENCE; PIGMENTED NEVUS; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR GENE; CELL CYCLE; CELL PROLIFERATION; COMPARATIVE STUDY; DNA REPLICATION; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; SKIN TUMOR; TIME; TUMOR CELL LINE;

ADULT; AGED; AGED, 80 AND OVER; AZACITIDINE; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DNA METHYLATION; DNA REPLICATION; ENZYME INHIBITORS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HOMEODOMAIN PROTEINS; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEVUS, PIGMENTED; PAIRED BOX TRANSCRIPTION FACTORS; RNA, MESSENGER; SKIN NEOPLASMS; TIME FACTORS; TRANSFECTION; TUMOR SUPPRESSOR PROTEINS;

EID: 58149184588     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000095     Document Type: Article

References (36)

1. Noll M: Evolution and role of Pax genes. Curr Opin Genet Dev 3: 595-605, 1993.
2. Dahl E, Koseki H and Balling R: Pax genes and organogenesis. Bioessays 19: 755-765, 1997.
3. Chi N and Epstein JA: Getting your Pax straight: pax proteins in development and disease. Trends Genet 18: 41-47, 2002.
4. Wallin J, Wilting J, Koseki H, Fritsch R, Christ B and Balling R: The role of Pax-1 in axial skeleton development. Development 120: 1109-1121, 1994.
5. Epstein DJ, Vogan KJ, Trasler DG and Gros P: A mutation within intron 3 of the Pax-3 gene produces aberrantly spliced mRNAtranscripts in the splotch (Sp) mouse mutant. Proc Natl Acad Sci USA 90: 532-536, 1993.
6. Sanyanusin P, Schimmenti LA, McNoe LA, et al: Mutation of the PAX2 gene in a family with optic nerve colobomas, renal anomalies and vesicoureteral reflux. Nat Genet 9: 358-364, 1995.
7. Glaser T, Jepeal L, Edwards JG, Young SR, Favor J and Maas RL: PAX6 gene dosage effect in a family with congenital cataracts, aniridia, anophthalmia and central nervous system defects. Nat Genet 7: 463-471, 1994.
8. Galili N, Davis RJ, Fredericks WJ, et al: Fusion of a fork head domain gene to PAX3 in the solid tumour alveolar rhabdomyosarcoma. Nat Genet 5: 230-235, 1993.
9. Shapiro DN, Sublett JE, Li B, Downing JR and Naeve CW: Fusion of PAX3 to a member of the forkhead family of transcription factors in human alveolar rhabdomyosarcoma. Cancer Res 53: 5108-5112, 1993.
10. Kroll TG, Sarraf P, Pecciarini L, Chen CJ, Mueller E, Spiegelman BM and Fletcher JA: PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma. Science 289: 1357-1360, 2000.
11. Cazzaniga G, Daniotti M, Tosi S, et al: The paired box domain gene PAX5 is fused to ETV6/TEL in an acute lymphoblastic leukemia case. Cancer Res 61: 4666-4670, 2001.
12. Schulte TW, Toretsky JA, Ress E, Helman L and Neckers LM: Expression of PAX3 in Ewing's sarcoma family of tumors. Biochem Mol Med 60: 121-126, 1997.
13. Tagge EP, Hanson P, Re GG, Othersen HB Jr, Smith CD and Garvin AJ: Paired box gene expression in Wilms' tumor. J Pediatr Surg 29: 134-141, 1994.
14. Kozmik Z, Sure U, Rüedi D, Busslinger M and Aguzzi A: Deregulated expression of PAX5 in medulloblastoma. Proc Natl Acad Sci USA 92: 5709-5713, 1995.
15. Fabbro D, Di Loreto C, Beltrami CA, Belfiore A, Di Lauro R and Damante G: Expression of thyroid-specific transcription factors TTF-1 and PAX-8 in human thyroid neoplasms. Cancer Res 54: 4744-4749, 1994.
16. Maulbecker CC and Gruss P: The oncogenic potential of Pax genes. EMBO J 12: 2361-2367, 1993.
17. Muratovska A, Zhou C, He S, Goodyer P and Eccles MR: Paired-Box genes are frequently expressed in cancer and often required for cancer cell survival. Oncogene 22: 7989-7997, 2003.
18. Scholl FA, Kamarashev J, Murmann OV, Geertsen R, Dummer R and Schäfer BW: PAX3 is expressed in human melanomas and contributes to tumor cell survival. Cancer Res 61: 823-826, 2001.
19. Dehbi M, Ghahremani M, Lechner M, Dressler G and Pelletier J: The paired-box transcription factor, PAX2, positively modulates expression of the Wilms' tumor suppressor gene (WT1). Oncogene 13: 447-453, 1996.
20. Fraizer GC, Shimamura R, Zhang X and Saunders GF: PAX 8 regulates human WT1 transcription through a novel DNA binding site. J Biol Chem 272: 30678-30687, 1997.
21. Stuart ET, Haffner R, Oren M and Gruss P: Loss of p53 function through PAX-mediated transcriptional repression. EMBO J 14: 5638-5645, 1995.
22. Okubo Y, Hamada J, Takahashi Y, et al: Transduction of HOXD3-antisense into human melanoma cells results in decreased invasive and motile activities. Clin Exp Metastasis 19: 503-511, 2002.
23. Miyamoto T, Kakizawa T, Ichikawa K, Nishio S, Kajikawa S and Hashizume K: Expression of dominant negative form of PAX4 in human insulinoma. Biochem Biophys Res Commun 282: 34-40, 2001.
24. Takahashi Y, Hamada J, Murakawa K, et al: Expression profiles of 39 HOX genes in normal human adult organs and anaplastic thyroid cancer cell lines by quantitative real-time RT-PCR system. Exp Cell Res 293: 144-153, 2004.
25. Robson EJ, He SJ and Eccles MR: A PANorama of PAX genes in cancer and development. Nat Rev Cancer 6: 52-62, 2006.
26. Khoubehi B, Kessling AM, Adshead JM, Smith GL, Smith RD and Ogden CW: Expression of the developmental and oncogenic PAX2 gene in human prostate cancer. J Urol 165: 2115-2120, 2001.
27. Barr FG, Fitzgerald JC, Ginsberg JP, Vanella ML, Davis RJ and Bennicelli JL: Predominant expression of alternative PAX3 and PAX7 forms in myogenic and neural tumor cell lines. Cancer Res 59: 5443-5448, 1999.
28. Gnarra JR and Dressler GR: Expression of Pax-2 in human renal cell carcinoma and growth inhibition by antisense oligonucleotides. Cancer Res 55: 4092-4098, 1995.
29. Dehbi M and Pelletier J: PAX8-mediated activation of the wt1 tumor suppressor gene. EMBO J 15: 4297-4306, 1996.
30. Zhou YH, Tan F, Hess KR and Yung WK: The expression PAX6, PTEN, vascular endothelial growth factor, and epidermal growth factor receptor in gliomas: relationship to tumor grade and survival. Clin Cancer Res 9: 3369-3375, 2003.
31. Zhou YH, Wu X, Tan F, et al: PAX6 suppresses growth human glioblastoma cells. J Neurooncol 71: 223-229, 2005.
32. Dohrmann C, Gruss P and Lemaire L: Pax genes and the differentiation of hormone-producing endocrine cells in the pancreas. Mech Dev 92: 47-54, 2000.
33. Sosa-Pineda B, Chowdhury K, Torres M, Oliver G and Gruss The Pax4 gene is essential for differentiation of insulin-producing α-cells in the mammalian pancreas. Nature 386: 399-402, 1997.
34. St-Onge L, Sosa-Pineda B, Chowdhury K, Mansouri A and Gruss P: Pax6 is required for differentiation of glucagons-producing α-cells in mouse pancreas. Nature 387: 406-409, 1997.
35. Morita R, Fujimoto A, Hatta N, Takehara K and Takata M: Comparison of genetic profiles between primary melanomas and their metastases reveals genetic alterations and clonal evolution during progression. J Invest Dermatol 111: 919-924, 1998.
36. Gordon KB, Thompson CT, Char DH, O'Brien JM, Kroll S, Ghazvini S and Gray JW: Comparative genomic hybridization in the detection of DNA copy number abnormalities in uveal melanoma. Cancer Res 54: 4764-4768, 1994.